Harrison Jessica J, Hobson-Peters Jody, Bielefeldt-Ohmann Helle, Hall Roy A
Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, University of Queensland, St. Lucia, Brisbane, QLD 4072, Australia.
School of Veterinary Science, University of Queensland, Gatton, QLD 4343, Australia.
Vaccines (Basel). 2021 Oct 22;9(11):1230. doi: 10.3390/vaccines9111230.
Vector-borne flaviviruses are responsible for nearly half a billion human infections worldwide each year, resulting in millions of cases of debilitating and severe diseases and approximately 115,000 deaths. While approved vaccines are available for some of these viruses, the ongoing efficacy, safety and supply of these vaccines are still a significant problem. New technologies that address these issues and ideally allow for the safe and economical manufacture of vaccines in resource-poor countries where flavivirus vaccines are in most demand are urgently required. Preferably a new vaccine platform would be broadly applicable to all flavivirus diseases and provide new candidate vaccines for those diseases not yet covered, as well as the flexibility to rapidly pivot to respond to newly emerged flavivirus diseases. Here, we review studies conducted on novel chimeric vaccines derived from insect-specific flaviviruses that provide a potentially safe and simple system to produce highly effective vaccines against a broad spectrum of flavivirus diseases.
通过媒介传播的黄病毒每年在全球导致近5亿人感染，造成数百万例使人虚弱的严重疾病，并导致约11.5万人死亡。虽然针对其中一些病毒有已获批的疫苗，但这些疫苗的持续有效性、安全性和供应仍然是一个重大问题。迫切需要新技术来解决这些问题，并理想地实现在最需要黄病毒疫苗的资源匮乏国家安全、经济地生产疫苗。最好是一种新的疫苗平台能广泛适用于所有黄病毒疾病，为尚未涵盖的疾病提供新的候选疫苗，并具备迅速转向应对新出现的黄病毒疾病的灵活性。在此，我们综述了对源自昆虫特异性黄病毒的新型嵌合疫苗的研究，这些疫苗提供了一个潜在安全且简单的系统，以生产针对多种黄病毒疾病的高效疫苗。
